# Canton Venture Capital

> Canton Venture Capital is a VC fund in Guangzhou backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Guangzhou, China
- Total investments: 7
- Last investment: Aug 2022
- Lead investor: 29%
- Last updated: Aug 2026
- Website: http://www.c-vcc.com

Canton Venture Capital is an equity investment management firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Medical | 3 | 43% |
| Health Care | 3 | 43% |
| Sales | 1 | 14% |
| Hospital | 1 | 14% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Post-IPO Equity | 2 | 29% |
| Seed | 1 | 14% |
| Series C | 1 | 14% |
| Series F | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Camelot Electronic Technology | Camelot Electronic Technology is a manufacturer of automotive PCB products. Camelot's products are used in automotive electronics (core components of new energy vehicles, traditional auto parts), communication electronics, industrial control, consumer electronics, medical equipment, and other fields. |  | Post-IPO Equity | Aug 26, 2022 |  |
| Bioblue Technology | Bioblue Technology focuses on the research and development of early tumor diagnosis products such as serum autoantibody profiles of lung cancer. Bioblue Technology's first key product project for early-stage lung cancer non-invasive screening independently adopts the world's leading liquid-phase chip technology, which has importantdiagnostic value for early screening and diagnosis of lung cancer. |  | Series A | Jul 05, 2022 |  |
| Haina Water Group | Haina Water Group manages the ecological environment intelligently. They provide research and development, design, investment, construction, and operation of environmental water projects. They offer customers systematic solutions. |  | Post-IPO Equity | Jan 01, 2022 |  |
| Magpie Pharmaceuticals | Magpie Pharmaceuticals specialize in the research and development of first-in-class drugs. The company focuses on the structural modification and transformation of active natural product monomers in traditional Chinese medicines (TCM), as well as small molecular compounds currently in clinical use. | $14M | Series C | Apr 20, 2020 |  |
| Shun Taimai bud Group | Shun Taimai bud Group engages in the beer and malt production business. |  | Series F | Feb 24, 2020 |  |
| Bainian Yihao | Established in 2017, the 100-year nickname is positioned in the transformation of biomedical innovations and new drug research and development institutions, mainly for the development of new drugs such as CAR-T cell therapy and tumor vaccines, such as immunotherapy, gene therapy, stem cell therapy and small molecule targeted drugs. . | $21.3M | Series A | Apr 08, 2019 |  |
| Ruizhen Regenerative Medicine | Ruizhen Regenerative Medicine focuses on the scientific research and deep clinical transformation of regenerative medicine technology with iPS as the core. | $13.8M | Seed |  |  |

7 of 7 investments shown.

## Co-investors
- [BOC & Utrust Private Equity Fund Management](https://shizune.co/investors/profile/boc-utrust-private-equity-fund-management) — VC Fund, 1 deal together
- [CF Capital](https://shizune.co/investors/profile/cf-capital-5993) — VC Fund, 1 deal together
- [Chengdu Tianfu International Bio-Town Investment & Development](https://shizune.co/investors/profile/chengdu-international-bio-town-investment-and-development) — VC Fund, 1 deal together
- [CXVC](https://shizune.co/investors/profile/cxvc) — VC Fund, 1 deal together
- [DT Capital Partners](https://shizune.co/investors/profile/dt-capital-partners) — VC Fund, 1 deal together
- [Essence Capital](https://shizune.co/investors/profile/essence-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Canton Venture Capital invest in?

Canton Venture Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Canton Venture Capital last invest?

The most recent investment recorded for Canton Venture Capital closed in Aug 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co